Field Engineering Specialist - Mass Spectrometry
About the job
- A high school diploma and two years of technical school, equivalent military training, or equivalent work experience.
- Five years of progressive experience repairing or servicing mechanical or system hardware and software, networking, or wireless networking; alternatively, a bachelor's degree in Biomedical Engineering, Mechanical Engineering, Electrical Engineering, Chemistry, or a related field plus one to two years of progressive experience repairing or servicing complex mechanical or system hardware and software, networking, or wireless networking.
- Successful completion of training or certification as defined by RD Services leadership and policy.
- Ability to travel, including overnight travel.
- Ability to service, repair, calibrate, and install mass spectrometry systems and associated automation.
- Ability to diagnose and resolve mechanical, electronic, software, and gas or fluidic failures.
- Ability to provide basic operational and workflow support to customer operators and field application specialists.
- Ability to maintain accurate service documentation using a customer relationship management system.
- Provide primary field engineering support for cobas i601 mass spectrometry systems across customer laboratories in the assigned territory.
- Service, repair, calibrate, and install cobas i601 mass spectrometry systems and associated automation.
- Maintain ultra-high vacuum pumps, atmospheric pressure ionization sources, electromagnetic ion optics, oscillating RF/DC quadrupoles, and high-pressure liquid chromatography fluidic pumps.
- Perform preventive maintenance by rebuilding and oiling vacuum pumps, cleaning ion sources and sampling capillaries, replacing liquid chromatography components, and optimizing mass spectrometry performance.
- Use total ion chromatograms, mass spectra, mass-to-charge ratios, and tuning logs to troubleshoot hardware performance issues.
- Support routine applications workflows and advise customers on fluidic maintenance, vacuum integrity, and minimizing chemical interference or contamination.
- Collaborate with National Field Engineering Specialists and Advanced Engineering Specialists on complex accounts, rollouts, and technical escalations.
- Serve as the primary technical contact for service-related issues and perform scheduled preventive maintenance.
- Participate in on-call rotations and provide after-hours or weekend support as required.
- Maintain accurate service documentation in Roche's customer relationship management system.
- Four or more years of experience with a bachelor's degree in a relevant field, or eight or more years of progressive technical experience, servicing analytical chemistry instrumentation, clinical mass spectrometry platforms, or high-pressure fluidic systems.
- Hands-on experience operating, servicing, or troubleshooting liquid chromatography-tandem mass spectrometry platforms, liquid chromatography, high-performance liquid chromatography, ultra-high-performance liquid chromatography, or vacuum systems.
- Familiarity with vacuum leak detectors, mass calibration tuning fluids, RF/DC voltage tools, and nitrogen gas flow measurement.
- Basic understanding of gas-phase physics, mass-to-charge ratio detection, and sample matrix effects.
- Experience working cross-functionally with field application specialist colleagues and leads to resolve operational issues.
- Written and verbal communication skills and experience building positive relationships with laboratory operators and managers.
About the company
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
See people who can refer or advise you
Simplify's Take
What believers are saying
- Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
- pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
- Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.
What critics are saying
- Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
- Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
- If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.
What makes Roche unique
- Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
- Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
- Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.
Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.
Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.
Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.
Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.